New Millennium Group LLC trimmed its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 99.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,567 shares of the biotechnology company's stock after selling 212,742 shares during the period. New Millennium Group LLC's holdings in ADMA Biologics were worth $31,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Mark Sheptoff Financial Planning LLC acquired a new position in ADMA Biologics during the 4th quarter worth $35,000. Vision Financial Markets LLC bought a new stake in shares of ADMA Biologics during the fourth quarter worth $51,000. Tsfg LLC acquired a new position in shares of ADMA Biologics during the first quarter valued at $51,000. Farther Finance Advisors LLC lifted its stake in shares of ADMA Biologics by 1,149.1% during the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock valued at $53,000 after acquiring an additional 2,505 shares during the period. Finally, AlphaQuest LLC bought a new position in ADMA Biologics in the fourth quarter valued at about $84,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.
ADMA Biologics Stock Up 1.5%
Shares of NASDAQ ADMA traded up $0.26 during mid-day trading on Wednesday, hitting $18.14. The company had a trading volume of 3,086,570 shares, compared to its average volume of 3,704,011. The company has a current ratio of 6.58, a quick ratio of 3.36 and a debt-to-equity ratio of 0.22. The firm has a 50-day simple moving average of $20.40 and a two-hundred day simple moving average of $18.73. The company has a market capitalization of $4.33 billion, a PE ratio of 21.34 and a beta of 0.43. ADMA Biologics Inc has a one year low of $10.21 and a one year high of $25.67.
ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.02). The firm had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The company's revenue for the quarter was up 40.2% on a year-over-year basis. During the same quarter last year, the business posted $0.08 earnings per share. On average, equities analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current year.
Analyst Ratings Changes
Several analysts have weighed in on the company. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Finally, Raymond James Financial raised their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th.
Check Out Our Latest Stock Analysis on ADMA
Insider Transactions at ADMA Biologics
In related news, Director Lawrence P. Guiheen sold 20,000 shares of ADMA Biologics stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $20.96, for a total transaction of $419,200.00. Following the completion of the sale, the director directly owned 94,830 shares of the company's stock, valued at approximately $1,987,636.80. This trade represents a 17.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Jerrold B. Grossman sold 10,000 shares of the business's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the sale, the director owned 478,194 shares of the company's stock, valued at $10,190,314.14. This trade represents a 2.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 464,621 shares of company stock worth $9,644,269. 3.50% of the stock is owned by insiders.
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Articles
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
